<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>After <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD), vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD) is the most common cause of <z:hpo ids='HP_0000726'>dementia</z:hpo> among the elderly </plain></SENT>
<SENT sid="1" pm="."><plain>Abnormalities in neurotransmitter pathways are common pathogenic mechanisms shared by AD and VaD </plain></SENT>
<SENT sid="2" pm="."><plain>For one month we studied the effects of <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi>, an <z:chebi fb="0" ids="38462">acetylcholinesterase inhibitor</z:chebi> (5 mg daily), on the cognitive system using P300 auditory event-related potentials (P300) and neuropsychological tests in 10 patients affected by probable VaD according to the NINDS-AIREN criteria </plain></SENT>
<SENT sid="3" pm="."><plain>Our data showed a significant improvement of neuropsychological items and P300 latency after one month of <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> treatment </plain></SENT>
<SENT sid="4" pm="."><plain>In conclusion both P300 and neuropsychological tests are indicated in patients with VaD to confirm the efficacy of <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> treatment during follow-up </plain></SENT>
</text></document>